Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s…
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift…
Priscilla Chan (R) and her husband Mark Zuckerberg announce the Chan Zuckerberg Initiative to “cure, prevent or manage all disease” by the end of the century during a news conference at UCSF Mission Bay in San Francisco. Beck Diefenbach | Reuters Biohub, a Chan Zuckerberg Initiative-funded non-profit research organization, announced Thursday that it will open…
An empty street in Toulouse, France, on June 22, 2026. France experiences its second heatwave of the year, with temperatures in Toulouse reaching or surpassing 40?C. MeteoFrance reports that this day is expected to be one of the hottest on record. Nurphoto | Nurphoto | Getty Images Several countries in Europe have issued red weather…
The growing push to restrict Americans from using federal food aid to buy certain processed or sugary products is creating a new challenge for some of the biggest U.S. food and beverage companies. The U.S. Department of Agriculture as of May had approved food restriction waivers for Supplemental Nutrition Assistance Program benefits in 23 states,…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,”…
Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to…
Thomas Fuller | SOPA Images | Lightrocket | Getty Images UniQure plans to seek FDA approval of its experimental gene therapy for Huntington’s disease, the company said Wednesday, months after previous agency leaders criticized the evidence backing the application. UniQure said the FDA in a recent meeting communicated that a three-year analysis from a Phase…
Public markets are beginning to reopen for biotech companies after several years of muted activity. But the strongest companies may still be more likely to sell themselves to Big Pharma rather than testing investor appetite in an IPO, according to JPMorgan’s top healthcare dealmakers. The IPO window has reopened for high-quality biotech companies, but investors…
Sheldon Cooper | Lightrocket | Getty Images Centene said it offered buyouts to some employees on Monday, as the health insurer grapples with higher medical costs, funding cuts and membership declines. “Centene is positioning the company to lead the future of healthcare — working to deliver a simpler and better experience for our members and…
